semaglutide patent protection The upcoming expiry of the in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the development will open Semaglutide Patent Expiry to Boost

Weight loss outcomes among early high responders to exenatide treatment: a randomized, placebo controlled study in overweight and obese women

A GLP, like Wegovy or Ozempic, or GLP/GIP, like Mounjaro or Zepbound, works by regulating blood sugar, reducing appetite, and slowing digestion

Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities

Although the results of Benvenistes so-called digital biology experiments were later attributed to an experimenter effect [Jonas et al

Pregnancy and breastfeeding No human safety data exists for these groups